SynthesisCancer reports (Hoboken, N.J.)2026
Stage at Diagnosis and Molecular Subtype Distribution of Breast Cancer in Sub-Saharan Africa: A Systematic Review.
Synthesis in Cancer reports (Hoboken, N.J.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThis systematic review analyzes the stage at diagnosis of breast cancer and the distribution of molecular subtypes across sub-Saharan Africa between January 2014 and December 2025. A search on Medline, African Journals Online, Web of Science, and Embase was performed. RECENT
findingsDistribution of molecular subtypes, such as Luminal A or B, HER2-enriched and Triple-negative, was also analyzed. From 125 selected studies comprising 42689 patients with staged breast cancer, 63.1% were diagnosed at a late stage, with regional variations (74.5% in Middle Africa, 68.5% in Eastern Africa, 71% in Western Africa, and 55.2% in Southern Africa).Luminal subtypes (A and B) accounted for 68.2% of cases, followed by triple-negative breast cancer (21.1%) and HER2-enriched tumors (10.6%).
conclusionsOur findings provide an updated synthesis of the stage at diagnosis of breast cancer in sub-Saharan Africa since January 2014. Although a high proportion of patients continue to present at late stage, comparisons with earlier reports should be interpreted cautiously due to heterogeneity in study populations, regional representation, and reporting practices. These findings should be interpreted as an updated regional synthesis rather than evidence of a confirmed temporal improvement in stage at diagnosis.
trial registrationThe review protocol was not registered in PROSPERO which we acknowledge as a limitation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.